"10.1371_journal.pone.0027996","plos one","2011-12-22T00:00:00Z","Erika Suzuki; Susan Demo; Edgar Deu; Jonathan Keats; Shirin Arastu-Kapur; P Leif Bergsagel; Mark K Bennett; Christopher J Kirk","Onyx Pharmaceuticals, South San Francisco, California, United States of America; Stanford University, Stanford, California, United States of America; Translational Genomics Research Institute, Phoenix, Arizona, United States of America; Mayo Clinic, Scottsdale, Arizona, United States of America","Conceived and designed the experiments: MKB SD CJK ES SA-K ED JK. Performed the experiments: ES SA-K JK ED SD. Analyzed the data: ES SD JK SA-K MKB CJK. Contributed reagents/materials/analysis tools: PLB MKB CJK. Wrote the paper: SA-K ES CJK JK ED.","Christopher J. Kirk, Erika Suzuki and Shirin Arastu-Kapur are current employees of Onyx Pharmaceuticals. There are no patents to declare, however this study is in support of the mechanism of action of Carfilzomib, a product currently in development from Onyx. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2011","12","Erika Suzuki","ES",8,TRUE,7,5,6,5,TRUE,TRUE,FALSE,0,NA,FALSE
